임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 21-06-10 11:24
논문번호 271
논문제목(영문) Impacts of renin-angiotensin system inhibitors on two-year clinical outcomes in diabetic and dyslipidemic acute myocardial infarction patients after a successful percutaneous coronary intervention using newer-generation drug-eluting stents
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Kim YH, Her AY,
교신저자명 Kim YH
공동저자명 Jeong MH, Kim BK, Hong SJ, Kim S, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y
게제년월일 2020-07-24
ISSN 0025-7974
Impact Factor 1.552
학술지명 MEDICINE
서지사항 0집 / 99권 / 30호,   페이지(e21289 - e21289)
요약초록문
(Abstract) 입력		 This study investigated the impacts of renin-angiotensin system inhibitors (RASIs) on 2-year clinical outcomes in diabetes and dyslipidemic acute myocardial infarction (AMI) patients after a successful percutaneous coronary intervention (PCI) using newer-generation drug-eluting stents (DESs). A total of 16,997 AMI patients were enrolled, and divided into four groups based on the presence or absence of diabetes and dyslipidemia as follows: diabetes -/dyslipidemia -(group A, 11,132 patients), diabetes +/dyslipidemia - (group B, 3,860 patients), diabetes -/dyslipidemia + (group C, 1,328 patients), and diabetes +/dyslipidemia + (group D, 677 patients). The clinical endpoint was the occurrence of major adverse cardiac events (MACEs), the composite of total death, recurrent myocardial infarction (re-MI), and any repeat revascularization, including target lesion revascularization (TLR), target vessel revascularization (TVR), and non-target vessel revascularization (non-TVR). After RASIs therapy, the cumulative incidences of MACEs (adjusted hazard ratio [aHR], 1.330; 95% confidence interval [CI], 1.022-1.732;P = .034), any repeat revascularization (aHR, 1.584; 95% CI, 1.092-2.298;P = .015), TLR, and TVR were significantly higher in group B than group C. However, the cumulative incidences of all-cause death, cardiac death, re-MI, and non-TVR were similar in groups B and C. In this study, under the newer-generation DESs era, repeat revascularization rate reduction benefit of RASIs therapy in diabetic AMI patients was lesser than that in dyslipidemic AMI patients. However, larger randomized controlled studies are needed to confirm these results in the future.
파일  C271. Impacts of renin-angiotensin system inhibitors on two-year clinical out~.pdf (1.0M) DATE : 2021-06-10 11:24:29